Intellia Therapeutics NTLA Ratios (2015-2026)

NASDAQ NTLA
$12.74 +0.06 (+0.47%)
At close: Sep 4, 2026 · 4:00 PM EDT
Reported Financials

Intellia Therapeutics Quarterly Ratios

Periods 46 quarters
Latest Jun 2026

Intellia Therapeutics reported a net margin of -1,396.57% for the quarter ended Jun 2026. These financial ratios cover 46 quarters of results from Mar 2015 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Ratios Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Profitability
EBT Margin
-994.50%-621.69%-1,277.16%-695.64%-780.83%-771.63%-793.10%-880.40%-987.05%6,647.52%-350.34%-1,820.05%-1,455.91%-977.29%-674.83%-720.21%-760.14%-400.72%-633.49%-1,396.57%
EBIT Margin
-999.35%-625.60%-1,281.96%-700.65%-795.49%-811.07%-888.13%-973.47%-1,093.29%7,297.44%-394.00%-1,998.61%-1,588.96%-1,059.86%-726.57%-772.17%-808.86%-428.86%-668.08%-1,472.25%
EBITDA Margin
-999.35%-625.60%-1,281.96%-700.65%-795.49%-811.07%-888.13%-973.47%-1,093.29%7,297.44%-394.00%-1,998.61%-1,588.96%-1,059.86%-726.57%-772.17%-808.86%-428.86%-668.08%-1,472.25%
Operating Margin
-999.35%-625.60%-1,281.96%-700.65%-795.49%-811.07%-888.13%-973.47%-1,093.29%7,297.44%-394.00%-1,998.61%-1,588.96%-1,059.86%-726.57%-772.17%-808.86%-428.86%-668.08%-1,472.25%
Net Margin
-994.50%-621.69%-1,277.16%-695.64%-780.83%-771.63%-793.10%-880.40%-987.05%6,647.52%-350.34%-1,820.05%-1,455.91%-977.29%-674.83%-720.21%-760.14%-400.72%-633.49%-1,396.57%
FCF Margin
-965.57%-447.48%-742.29%-618.52%-623.87%-690.94%-897.67%-696.07%-881.53%4,933.44%-425.67%-850.91%-945.19%-669.38%-900.13%-701.02%-558.18%-301.56%-780.34%-1,108.79%
Efficiency
Assets AverageAssets Avg.
1.00B1.31B1.25B1.16B1.10B1.30B1.47B1.37B1.28B1.27B1.28B1.23B1.18B1.18B1.09B0.94B0.91B0.88B0.80B0.81B
Asset Utilization RatioAsset Util.
0.030.030.030.040.050.040.040.040.040.030.040.040.040.050.040.060.060.080.080.07
Valuation
Price to EarningsP/E
-139.20-110.21-38.24-40.31-41.38-29.02-32.84-30.10-23.80-22.25-26.14-17.37-15.77-9.46-6.56-9.63-19.09-11.34-16.20-22.15
Price to SalesP/S
0.00B685.17488.41280.38323.07223.90260.46265.03234.93-0.00B91.59316.19229.6092.4144.2869.36145.0945.43102.61309.32
Price to BookP/B
9.018.475.764.475.202.462.763.262.722.702.562.272.171.360.94-1.382.671.562.493.26
Enterprise Value
9.17B8.06B4.64B3.06B3.46B1.85B2.35B2.69B1.96B1.92B1.86B1.51B1.43B0.59B0.23B0.53B1.49B0.60B1.17B1.93B
EV to EBIT
-127.44-100.19-32.17-31.12-32.76-16.77-20.99-20.36-14.97-13.75-16.31-10.85-9.90-4.31-1.92-4.80-13.35-6.04-11.62-17.13
EV to EBITDA
-127.44-100.19-32.17-31.12-32.76-16.77-20.99-20.36-14.97-13.75-16.31-10.85-9.90-4.31-1.92-4.80-13.35-6.04-11.62-17.13
Market Capitalization
9.97B8.81B5.50B3.93B4.29B3.04B3.28B3.60B2.82B2.84B2.65B2.20B2.09B1.19B0.74B0.99B2.00B1.05B1.54B2.37B
Price to FCFP/FCF
-143.37-153.12-65.80-45.33-51.78-32.41-29.01-38.08-26.65-29.98-21.52-37.16-24.29-13.81-4.92-9.89-25.99-15.07-13.15-27.90
EV to FCF
-131.90-140.07-55.56-35.26-41.78-19.69-20.77-28.48-18.56-20.34-15.09-25.48-16.65-6.82-1.55-5.29-19.35-8.58-9.95-22.74
EV to CFO
-141.10-147.42-58.15-35.96-44.03-20.55-21.49-29.83-19.36-20.67-15.41-25.93-16.90-6.90-1.56-5.30-19.36-8.60-9.95-23.24
Return Ratios
Return on Sales [ROS]ROS
-999.35%-625.60%-1,281.96%-700.65%-795.49%-811.07%-888.13%-973.47%-1,093.29%7,297.44%-394.00%-1,998.61%-1,588.96%-1,059.86%-726.57%-772.17%-808.86%-428.86%-668.08%-1,472.25%
Return on Capital Employed [ROCE]ROCE
-25.37%-22.53%-32.58%-38.24%-44.34%-38.97%-31.19%-36.19%-40.75%-44.54%-43.75%-46.77%-49.94%-49.87%-55.44%-60.45%-58.50%-56.55%-58.11%-58.12%
Return on Assets [ROA]ROA
-22.80%-20.28%-29.16%-33.97%-38.71%-34.53%-27.63%-31.23%-34.50%-36.59%-36.46%-38.66%-41.28%-41.15%-45.68%-50.21%-48.83%-46.60%-49.34%-49.42%